


SAFit1

Cat. No.:	HY-102079		
CAS No.:	1643125-32-9		
Molecular Formula:	C ₄₂ H ₅₃ NO ₁₁		
Molecular Weight:	747.87		
Target:	FKBP		
Pathway:	Apoptosis; Autophagy; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 300 mg/mL (401.14 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.3371 mL	6.6857 mL	13.3713 mL
	5 mM	0.2674 mL	1.3371 mL	2.6743 mL
	10 mM	0.1337 mL	0.6686 mL	1.3371 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.08 mg/mL (2.78 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (2.78 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SAFit1 is a FK506 binding protein 51 (FKBP51)-specific inhibitor with a K_i of 4±0.3 nM^{[1][2]}.

IC₅₀ & Target

K_i: 4±0.3 nM (FKBP51), >50000 nM (FKBP52)^[1]

In Vitro

SAFit1 (1-1000 nM) potently stimulates neurite outgrowth in two neuronal cell lines (N2a and SH-SY5Y) as well as in primary hippocampal neurons. SAFit1 is active over a wide concentration range^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gaali S, et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol. 2015 Jan;11(1):33-7.

[2]. Sidibeh CO, et al. FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes. Endocrine. 2018 Oct;62(1):116-128.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA